We describe 6 pediatric patients (12 to 18 y) with relapsed or refractory Hodgkin lymphoma treated with consolidative Brentuximab vedotin (Bv) following reinduction chemotherapy and autologous stem cell transplantation. The progression-free survival after autologous stem cell transplantation was 12, 18, 22, 24, 30, and 30 months. Most patients tolerated Bv well although 2 patients developed grade 3 neuropathy that prevent them from completing the scheduled 16 doses of Bv. Consolidative Bv in children and adolescents, as currently recommended for adult patients with early relapsed or refractory Hodgkin lymphoma, is feasible but with some significant toxicities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000001703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Glob Reg Health Technol Assess
December 2024
Evidera, Waltham, Massachusetts - USA.
When should we use it? The role of brentuximab vedotin in 2024.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA.
The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL), in 2015 for maintenance after autologous transplantation in high-risk patients, and in 2018 for frontline therapy with doxorubicin, vinblastine, and dacarbazine for advanced stage cHL. Although the role of BV in cHL had been reasonably well-established, it is currently being challenged by the changing landscape of other highly effective novel agents, such as checkpoint inhibitor immunotherapies. In this review, we discuss the evolving role of BV in the management of cHL and ongoing studies attempting to define the optimal usage of this effective agent.
View Article and Find Full Text PDFWhen to use stem cell transplantation for classical Hodgkin lymphoma.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Lymphoma/Myeloma and Department of Stem Cell Transplantation/Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Hodgkin lymphoma (HL) is a rare hematologic malignancy with a bimodal distribution of incidence, with most patients diagnosed between the ages of 15 and 30 years and another peak in patients older than 55 years. It is estimated that in 2023, almost 9000 people were diagnosed with HL in the United States. Most patients will be cured using conventional chemotherapy and radiotherapy.
View Article and Find Full Text PDFBV and beyond: how to incorporate novel agents into PTCL management.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO.
Peripheral T-cell lymphomas (PTCLs) are a heterogenous yet aggressive group of lymphomas that arise from mature T- or NK-cell precursors. Nodal PTCLs include anaplastic large-cell lymphoma, PTCL not otherwise specified, and follicular helper T-cell lymphomas. Recent advances in understanding these heterogenous diseases have prompted investigation of novel agents to improve on treatment.
View Article and Find Full Text PDFAntibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.
Ann Emerg Med
December 2024
Department of Emergency Medicine, MD Anderson Cancer Center, Houston, TX.
Article Synopsis
- Antibody-drug conjugates are a new class of cancer treatments that are becoming more widely used, but they come with various toxicities and complications that need to be managed, especially in emergencies.
- Common side effects include diarrhea, nausea, rash, and peripheral neuropathy, while severe conditions like interstitial lung disease and sinusoidal obstruction syndrome can pose serious health risks.
- Rare but critical issues include cardiac effects, ocular problems, and tumor lysis syndrome, which require careful monitoring and prompt medical intervention.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!